Compare Best Buy Co Inc (BBY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Best Buy Co Inc trades at $82.86 (market cap $17.55B), while State Street SPDR S&P Biotech ETF trades at $159. The key difference: Best Buy Co Inc pays a 4.61% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Best Buy Co Inc nearer its low. Which is the better fit depends on your goals.
| BBY | XBI | |
|---|---|---|
Market Cap | $17.55B | — |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $90.17 | $164.28 |
52-Week Low | $55.52 | $86.92 |
Enterprise Value | $19.93B | — |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $83.24, up 0.98% on the day, near the consensus price target of $84.31. The stock shows a neutral technical signal with bullish moving averages. Recent earnings have consistently beaten estimates, and the company maintains solid profitability with a 39.1% ROE. Leadership changes, including a new CFO, and store format tests aim to drive future growth amid declining revenues.
The outlook is mixed: strong cash flow improvement and shareholder returns via dividends support upside, but revenue declines and competitive pressures pose risks. Analysts are cautious with a 'Hold' majority. Investors should weigh valuation attractiveness against execution challenges in a tough retail environment.
XBI trades at $158.81, up 0.49% today, with a bullish technical signal supported by moving averages. The ETF shows strong momentum with a 17% monthly gain and 75% annual return, driven by biotech sector strength. Analyst coverage is limited to one hold rating, while recent news highlights institutional buying interest and positive sector developments including M&A activity and drug trial successes.
The outlook remains positive given biotech's breakout from multi-year bear markets, though elevated volatility and policy risks persist. Key opportunities include AI-driven drug discovery and sustained M&A momentum, while risks involve sector-specific volatility and regulatory uncertainty. The ETF's equal-weight approach provides diversified exposure to biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
